Surgery

At the EnVision Summit Ophthalmology 2023 in Puerto Rico, Eva Kim, MD, made a presentation titled "ICL and Clear Lens Exchange: Choosing the Right Approach."

Bonnie An Henderson, MD, founder and program director of EnVision Summit, previews what attendees can expect at this year’s meeting - from its diverse faculty to an inclusive Youth Program, while also giving back to the community. The conference will take place February 17 to 20 at the El Conquistador Resort in Fajardo, Puerto Rico.

In a presentation at Bascom Palmer’s 2023 Angiogenesis, Exudation, and Degeneration conference in Miami, Pedro Lylyk, MD, said ophthalmic artery angioplasty could prove to be a treatment option for patients diagnosed with age-related macular degeneration.

Robert L. Stamper, MD, discusses some of the devices in development for measuring patients' intraocular pressure outside of doctors' office hours in his presentation at Glaucoma Research Foundation's annual Glaucoma Symposium.

Shan C. Lin, MD, provides an overview of the various intraocular lens technologies that are available, as well as considerations for contrast sensitivity and vision loss in patients at Glaucoma Research Foundation's annual Glaucoma Symposium.

Ying Han, MD, PhD, provides some key takeaways from her Glaucoma 360 2023 presentation, "Tube shunt update."

Kristen H. Ingenito, MBA, vice president and director of ophthalmics at Market Scope, discusses the volume of ophthalmologists offering interventional glaucoma treatment as well as emerging therapies in her presentation at the Glaucoma 360 New Horizons Forum.

The company noted that the product is a sterile, single-patient use, physician administered, ophthalmic gel preparation, containing no preservatives, that is safe and effective for ocular surface anesthesia.

Based on their findings, an international team of researchers is discouraging the application of atropine as a standard therapy for trabeculectomy surgery.

Patient-tailored techniques result in predicable outcomes for patients.

Investigators found that all patients had similar single surgery success rates but that minority patients had significantly worse vision outcomes and were more likely to have multiple retinal breaks.

With the safety and efficacy of phacoemulsification having increased to the point that it is no longer standard practice to examine patients the day after surgery, clinicians may be unfamiliar with the potential causes of reduced vision when presented with a patient in the immediate postoperative period.

Not only is canaloplasty designed to treat the entire conventional outflow pathway, facilitating flow through the trabecular meshwork, Schlemm canal, and collector channels, but it does so without a stent and without removing tissue.

According to one surgeon, the technique may reduce the need for biopsies.

Survey of academic chairs and residency directors recognizes centers of excellence in Best Clinical Care, Best Residency, Best Research, and Best Overall Programs.

Ophthalmology Times®' EyeCon co-chairs Peter J. McDonnell, MD, director of the Wilmer Eye Institute, and glaucoma specialist Oluwatosin U. Smith MD, from Glaucoma Associates of Texas, discuss some of the highlights of EyeCon 2022.

The Ernest E. Tschannen Eye Institute is dedicated to eye care and sight restoration through technology, pioneering research and eye care clinicians.

According to the company, the facility will serve as a hub of the EVO Lens-Based Experience for ophthalmic surgeons, staff and healthcare practitioners.

In a two-decade career as a researcher at Johnson & Johnson Surgical Vision, Piers has been a part of teams at the forefront of a number of innovations in IOLs. She discusses her career and the outlook for research and development in ophthalmology.

According to physicians, patients who do not undergo second procedure are more likely to develop glaucoma.

Contemporary scleral lenses work so well that stable vision in them cannot necessarily be taken as a sign that KC progression has stopped. Determination of KC progression requires advanced imaging.

Investigators find a link with a postoperative prolonged steroid response.

The SBL-3 ClearView clinical study, an FDA investigational device exemption clinical trial conducted at 18 sites across the US, is a prospective, subject-masked, randomized, two-arm study.

The deal adds pharmaceutical research and development capabilities and further expertise for future product pipeline. It also expands Alcon’s presence in the $20 billion global ophthalmic pharmaceutical category.

A recent study showed that only 6% of practicing ophthalmologists in the US identify as an underrepresented minority.

According to UC Davis researchers, more needs to be done for the field to reflect ethnic and racial diversity across the country.

This December, the Ophthalmology Times® EyeCon 2022 at the JW Marriott Marco Island Beach Resort in Florida will provide attendees with an end-of-year opportunity to meet their continuing medical education requirements. This activity has been approved for 12.50 AMA PRA Category 1 Credits™.

OVDs that are currently used in cataract surgery fit into different classes including higher viscosity cohesives, lower viscosity dispersives, viscoadaptives and higher viscosity dispersives.